Inhibikase Therapeutics (NYSE:IKT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $4.00 price target on the stock.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Zacks Research to a "hold" rating.
Inhibikase Therapeutics (NASDAQ:IKT) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants